A newly published study found that adults who received the recombinant shingles vaccine had a lower long-term burden of cardiovascular events than adults who received the older live shingles vaccine. That is a promising signal, but it does not prove that the vaccine prevents heart attacks or strokes, and it is not a reason to change heart medication. The research used a natural experiment created by the rapid U.S. transition from the live vaccine to the recombinant vaccine. It was not a randomized clinical trial, and the authors say clinical trials and mechanistic studies are still needed.
The practical response is to check your age, immune status, vaccination record and current symptoms—not to chase a headline or a percentage. The Centers for Disease Control and Prevention does not base its current shingles vaccine recommendation on cardiovascular prevention. The established goal is to prevent shingles and complications such as postherpetic neuralgia. If you are eligible, complete the recommended two-dose series. If you are pregnant, currently have shingles, have a history of a severe allergic reaction, or are receiving immune-suppressing treatment, discuss timing with a clinician.
Key takeaways
- The Nature Medicine study compared U.S. adults age 60 and older who received the older live shingles vaccine with those who received the recombinant vaccine around the time the country rapidly switched products.
- Over seven years, the recombinant-vaccine group had a 9% lower burden of a composite outcome that included ischemic heart disease, heart failure and ischemic stroke. That does not mean every person’s heart-attack risk fell by exactly 9%.
- The study reports an association, not definitive causation. It does not establish the vaccine as a cardiovascular drug.
- CDC recommends two doses of recombinant shingles vaccine for immunocompetent adults age 50 and older, generally two to six months apart.
- CDC also recommends two doses for adults age 19 and older who are or will be immunodeficient or immunosuppressed. In some circumstances, the second dose may be given one to two months after the first.
- Chest pressure, trouble breathing, facial drooping, speech difficulty or sudden one-sided weakness requires emergency help. Do not wait because symptoms happened after vaccination.
What happened: what the study actually compared
This was not a simple comparison of vaccinated people with unvaccinated people. That type of study can be distorted by the “healthy user” effect: people who obtain preventive vaccines may also exercise more, attend checkups, take prescribed medication more consistently and have better access to care. To reduce that bias, the researchers used the sharp U.S. transition from the older live attenuated shingles vaccine to the newer recombinant vaccine as a natural experiment. They compared health records for adults age 60 and older vaccinated immediately before the transition with records for adults vaccinated immediately after it.
The primary outcome combined ischemic heart disease, heart failure and ischemic stroke. According to the paper’s abstract, recombinant vaccination was associated with a 9% decrease in cardiovascular burden across seven years. The researchers measured restricted mean time lost, a survival-analysis measure. It would therefore be inaccurate to translate the result into “the shot lowers any individual’s chance of a heart attack by 9%” or “nine of every 100 people avoided heart disease.” The finding concerns a group-level difference in time burden from cardiovascular events.
In secondary results, the recombinant vaccine was associated with a 10% lower burden of ischemic heart disease and a 12% lower burden of heart failure in both sexes. Ischemic stroke burden was 12% lower among men. Atrial fibrillation burden was 7% lower, while the study did not find the same pattern across every other cardiac, peripheral vascular and cerebrovascular outcome. The association also weakened over time. Subgroup results are useful for generating hypotheses, but they can be more sensitive to sample composition, multiple comparisons and differences in medical coding.
Why researchers think the possibility is worth testing
Shingles occurs when varicella-zoster virus reactivates. Infection and inflammation may affect blood vessels and clotting, and earlier research has linked shingles episodes with a temporary increase in stroke and cardiovascular risk. That makes it biologically plausible that preventing shingles—or reducing its severity—could indirectly reduce cardiovascular burden. Researchers can also examine whether immune responses differ between the recombinant vaccine and the older live vaccine.
Plausibility is not proof. Clinical practice, insurance coverage, infection patterns, medication use, data quality and the characteristics of people seeking vaccination can all change across a product transition. Statistical adjustment and a natural-experiment design reduce some bias but cannot guarantee that every unmeasured difference disappears. Because this study compared two vaccine eras and two vaccine types, it also does not directly answer whether any shingles vaccination is better for the heart than no vaccination.
What the study does not say
- It does not say that the recombinant shingles vaccine is approved to prevent heart attacks, heart failure or strokes.
- It does not support reducing or stopping statins, blood-pressure medicine, antiplatelet drugs, anticoagulants or diabetes treatment.
- It does not show that vaccination before the recommended age or extra doses provide more heart protection.
- It does not establish that one dose offers the same protection as the recommended two-dose series.
- It does not make chest pain, shortness of breath or neurologic symptoms safe to watch at home.
Who is affected
Immunocompetent adults age 50 and older
CDC recommends two doses of recombinant shingles vaccine for adults age 50 and older with healthy immune systems. The usual interval is two to six months, and there is no maximum age. People may still be eligible if they previously had shingles or received the older live vaccine. A person who currently has an acute shingles episode should wait until that episode has resolved.
The cardiovascular study’s main population was age 60 and older. Do not combine that research threshold with CDC’s age-50 vaccination recommendation and conclude that heart protection has been demonstrated for everyone in their 50s. For that age group, the established rationale remains prevention of shingles and postherpetic neuralgia.
Immunocompromised adults age 19 and older
Adults age 19 and older who are or will be immunodeficient or immunosuppressed because of disease or therapy are also covered by CDC’s recommendation. The second dose is generally given two to six months after the first. When someone would benefit from completing the series before a period of greater immunosuppression, the second dose may be given one to two months after the first. A clinician who understands the treatment schedule and immune condition should make that timing decision.
Immunocompromised adults have an elevated risk of shingles complications, but that does not mean the cardiovascular percentages in this study can automatically be applied to them. Ask when vaccination is likely to produce the best immune response, whether it can be given with other vaccines and how it fits around infusions, surgery, transplant care or immune-suppressing medication.
People who previously had shingles or received the older vaccine
Shingles can recur, so prior illness does not automatically remove the need for vaccination. CDC does not specify a mandatory waiting period after a past episode, but the recombinant vaccine should not be given during an acute shingles episode. If a rash is still evolving or systemic symptoms and pain remain severe, obtain medical care and confirm when the acute illness has ended.
The older live shingles vaccine has not been available in the United States since November 2020. People who received it may still be advised to receive the recombinant series. CDC’s clinical guidance says to wait at least eight weeks after the live vaccine before administering the recombinant vaccine. If your old record is missing, check the pharmacy, previous health system and state immunization information system rather than inventing an estimated date.
People who are pregnant or have a severe allergy history
CDC’s patient guidance says people who are currently pregnant should wait to receive recombinant shingles vaccine. Anyone who had a severe allergic reaction to a vaccine component or a previous dose should tell the vaccinating clinician. Expected arm soreness or a day of fatigue is not the same as a severe allergy. Describe any breathing trouble, facial or throat swelling, widespread hives, fainting, timing and treatment after the prior dose.
What to do now: keep the vaccine plan and heart plan separate
1. Confirm eligibility first
Check more than your birthday. Determine whether you are an immunocompetent adult age 50 or older, or an adult age 19 or older who is or will be immunocompromised. If neither applies, do not use this observational study as the sole reason to seek early vaccination. A study population, FDA labeling and CDC recommendations are related but distinct.
2. Find the product and dates in your record
“I had a shingles shot” may not be enough information. Confirm whether it was the older live vaccine or the recombinant vaccine and whether you received one recombinant dose or completed both doses. Search your pharmacy account, patient portal, insurer’s claim history and state immunization system. Save a record that shows the vaccine, date and location, but do not send unnecessary personal identifiers through insecure messages.
3. Put the second dose on the calendar
For most immunocompetent adults age 50 and older, the standard interval is two to six months. The usual interval is also two to six months for immunocompromised adults, although a one-to-two-month interval may be used in specific circumstances. Schedule the second appointment when you receive the first dose and set both calendar and pharmacy reminders. If the recommended interval has already passed, contact the vaccination provider rather than assuming you must restart the series.
4. Plan for two or three days of possible side effects
CDC says temporary effects can include arm pain, fatigue, muscle pain, headache, chills, fever and stomach symptoms, usually resolving in two to three days. If possible, avoid placing the appointment immediately before strenuous work or a long drive, and plan for fluids and rest. CDC notes that over-the-counter pain medicines may help, but ibuprofen or acetaminophen is not suitable for everyone. People with kidney or liver disease, gastrointestinal bleeding, anticoagulant use or medication allergies should ask a clinician or pharmacist what is safe.
5. Continue cardiovascular treatment
Blood pressure, cholesterol, diabetes, atrial fibrillation, heart failure and coronary disease require their own treatment plans. Keep taking prescribed medication and continue blood-pressure checks, tobacco cessation, activity, sleep, nutrition and regular care. You may share the paper with your clinician, but the vaccine is not a substitute for established cardiovascular prevention.
6. Separate emergency warning signs from expected reactions
Arm soreness and fatigue are common after vaccination. Sudden chest pressure, shortness of breath, sweating, pain spreading to the jaw, back or arm, facial drooping, one-sided weakness, trouble speaking or understanding speech, or a sudden severe headache should not be watched at home. Note when symptoms began and call 911 in the United States. Do not drive yourself if emergency services are appropriate.
How to verify the information through official sources
- Eligibility and intervals: Use CDC’s clinical shingles vaccine recommendations to distinguish the schedule for adults age 50 and older from guidance for immunocompromised adults age 19 and older.
- Patient safety guidance: Use CDC’s patient shingles vaccination page for who should get vaccinated, when to wait, expected side effects and links about cost.
- The primary study: Confirm the paper’s title, journal, DOI, publication date, age group, comparison groups and outcome measure. Do not rely on a headline that turns “9% lower burden” into “9% heart disease prevention.”
- Your record: Ask the pharmacy or health system which shingles vaccine you received, how many doses were documented and on what dates.
- Your clinical decision: Provide the clinician with your immune-suppressing treatment, pregnancy status, severe allergy history, current shingles symptoms and cardiovascular medication list.
When reading the paper online, pay attention to the authors’ conclusion. They say the findings justify clinical trials and mechanistic studies of possible cardioprotective effects. That is a call for stronger evidence, not a declaration that clinical heart protection is already established. On CDC pages, check that you are reading the current page rather than an old screenshot or a short social-media summary.
Frequently asked questions
Does the shingles vaccine prevent heart attacks?
That has not been established. The natural experiment found a lower cardiovascular burden associated with the recombinant vaccine compared with the older live vaccine, but it was not a randomized clinical trial. The vaccine is not approved or recommended as a heart-attack prevention drug. Follow your clinician’s cardiovascular plan.
Does the 9% result mean my personal risk falls by 9%?
No. The study compared seven-year cardiovascular burden between groups using a restricted mean time lost measure. It is not a universal 9% relative-risk reduction or an individual absolute-risk estimate. Personal risk varies with age, prior disease, smoking, blood pressure, cholesterol, diabetes and treatment.
I am younger than 50. Should I get vaccinated for heart health?
The routine recommendation for immunocompetent adults begins at age 50. Adults age 19 and older may be eligible if they are or will be immunocompromised because of disease or therapy. Do not make an off-schedule decision based only on this study; review your circumstances with a clinician.
I already had shingles. Do I still need the vaccine?
People can have shingles more than once, and CDC recommends the recombinant vaccine for eligible adults even after a prior episode. There is no specific mandatory waiting period, but do not receive it while an acute shingles episode is underway. Confirm recovery and timing with a clinician.
I previously received Zostavax. What should I do?
You may still be advised to receive the recombinant vaccine. CDC clinical guidance calls for at least eight weeks between the older live vaccine and the recombinant vaccine. If you are unsure when you received it, search official records and ask the vaccination provider to set the interval.
I felt very sick after dose one. Can I skip dose two?
CDC advises completing the second dose even when the first caused expected temporary reactions. A severe allergic reaction or another serious event requires medical review before another dose. Bring details about the symptoms, onset, duration and treatment to that discussion.
Can it be given with other vaccines?
CDC says recombinant shingles vaccine can be administered at a different anatomic site during the same visit as other adult vaccines. A clinician or pharmacist can help plan timing based on your likely temporary reactions and treatment schedule.
Where can I report a possible adverse event?
Seek medical care first when symptoms are severe. In the United States, patients and clinicians can submit reports to the Vaccine Adverse Event Reporting System. A VAERS report does not by itself prove that a vaccine caused an event; the system is used to collect and evaluate safety signals.
Bottom line
The new study offers an important and encouraging clue about recombinant shingles vaccination and long-term cardiovascular burden. The accurate interpretation is that possible heart protection now deserves more rigorous testing. It does not mean vaccination rules or cardiovascular treatment changed overnight. Eligible adults should complete the two-dose series for the established purpose of preventing shingles and its complications, while managing heart risk through established medical care. Treat the research as a promising signal and base personal action on current CDC guidance and a clinician who knows your health history.